For the quarter ended March 2025, Heron Therapeutics (HRTX) reported revenue of $38.9 million, up 12.2% over the same period last year. EPS came in at $0.01, compared to -$0.02 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $37.08 million, representing a surprise of +4.93%. The company delivered an EPS surprise of +200.00%, with the consensus EPS estimate being -$0.01.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wa ...

Company Performance - Heron Therapeutics reported quarterly earnings of $0.01 per share, surpassing the Zacks Consensus Estimate of a loss of $0.01 per share, and improving from a loss of $0.02 per share a year ago, representing an earnings surprise of 200% [1] - The company posted revenues of $38.9 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 4.93%, compared to revenues of $34.67 million in the same quarter last year [2] - Over the last four quarters, Heron Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Heron Therapeutics shares have increased by approximately 39.2% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $37.68 million, and for the current fiscal year, it is $0.01 on revenues of $157.15 million [7] Industry Outlook - The Medical - Drugs industry, to which Heron Therapeutics belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can significantly impact stock performance [5][8]

Q1 2025 Earnings Call Heron Therapeutics May 6, 2025 Forward-looking Statements and Non-GAAP Disclosures This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date hereof and are subject to certain risks and uncertainties that could cause actual results to differ materially. Examples of forward-looking statements include, ...

Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call May 06, 2025 08:00 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 twenty twenty five Conference Call. At this time, all participants are in a listen only mode. Please be advised that today's conference is being recorded. After the speakers' presentation, there will be a question and answer session. To ask a question, please press 11 on your telephone I would now like to hand the conference over to your speaker ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (Address of principal executive of ...

Exhibit 99.1 Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates CARY, May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates. "We are off to a strong start in 2025, achieving record adjusted EBITDA for the first quarter. Building on our efforts to strength ...

Generated Q1 2025 Net Revenue of $38.9 million Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI® and APONVIE® patent litigations, including an agreed market entry date of June 1, 2032 Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today anno ...

— Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 —CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related t ...

Core Insights - Heron Therapeutics, Inc. has appointed Mark Hensley as Chief Operating Officer, bringing over fifteen years of experience in the pharmaceutical industry [1][2] - The CEO of Heron, Craig Collard, expressed confidence in Hensley's ability to drive operational efficiency and support the company's growth initiatives [2] - Hensley previously held senior leadership roles at Veloxis Pharmaceuticals, including CEO and COO, and has a strong background in sales and operations [2] Compensation and Inducement Awards - As part of his employment, Hensley will receive inducement awards including a non-statutory stock option for 500,000 shares, 500,000 restricted stock units, and a performance-based stock option for up to 900,000 shares [3] - The inducement options have a 10-year term with a four-year vesting schedule, with 25% vesting on the first anniversary and the remainder vesting monthly over the next three years [3] - The performance-based stock option vests based on achieving certain stock price goals during Hensley's employment [3] Company Overview - Heron Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations to improve patient care [4] - The company utilizes advanced science and patented technologies to create a portfolio of products aimed at enhancing the standard of care for acute care and oncology patients [4]

Company Overview - Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations to improve medical care [3] - The company utilizes advanced science, patented technologies, and an innovative approach to drug discovery and development [3] - Heron aims to advance the standard-of-care for acute care and oncology patients through its portfolio of products [3] Upcoming Events - The company will host a conference call and live webcast on May 6, 2025, at 8:00 a.m. ET to report first quarter 2025 financial results and discuss recent business highlights [1] - Participants can access the conference call via a registration link and are encouraged to join fifteen minutes early to avoid delays [2] - An archive of the teleconference and webcast will be available on Heron's website for 60 days following the call [2]